Do analysts prefer IBAC or QSI?

Quantum-Si has a consensus target price of $1.00, indicating a potential upside of 27.39%. Given Quantum-Si's stronger consensus rating and higher probable upside, analysts plainly believe Quantum-Si is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quantum-Si 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, IBAC or QSI?

IB Acquisition has higher earnings, but lower revenue than Quantum-Si. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IB Acquisition N/A N/A N/A N/A N/A Quantum-Si $2.44M 70.42 -$101.34M -$0.46 N/A

Does the media prefer IBAC or QSI?

In the previous week, Quantum-Si had 6 more articles in the media than IB Acquisition. MarketBeat recorded 8 mentions for Quantum-Si and 2 mentions for IB Acquisition. IB Acquisition's average media sentiment score of 0.83 beat Quantum-Si's score of 0.16 indicating that IB Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IB Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quantum-Si 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer QTRX or IBAC?

Quanterix presently has a consensus price target of $3.00, suggesting a potential downside of 5.66%. Given Quanterix's stronger consensus rating and higher probable upside, equities research analysts plainly believe Quanterix is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quanterix 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, QTRX or IBAC?

IB Acquisition has lower revenue, but higher earnings than Quanterix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quanterix $138.90M 1.08 -$107.15M -$2.63 N/A IB Acquisition N/A N/A N/A N/A N/A

Does the media favor QTRX or IBAC?

In the previous week, Quanterix had 2 more articles in the media than IB Acquisition. MarketBeat recorded 4 mentions for Quanterix and 2 mentions for IB Acquisition. IB Acquisition's average media sentiment score of 0.83 beat Quanterix's score of 0.46 indicating that IB Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quanterix 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IB Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CDXS or IBAC?

Codexis currently has a consensus target price of $6.50, suggesting a potential upside of 374.45%. Given Codexis' stronger consensus rating and higher probable upside, equities analysts plainly believe Codexis is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Codexis 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, CDXS or IBAC?

IB Acquisition has lower revenue, but higher earnings than Codexis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Codexis $70.39M 2.13 -$43.97M -$0.34 N/A IB Acquisition N/A N/A N/A N/A N/A

Is CDXS or IBAC more profitable?

IB Acquisition has a net margin of 0.00% compared to Codexis' net margin of -39.55%. IB Acquisition's return on equity of 0.00% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Codexis -39.55% -74.36% -23.58% IB Acquisition N/A N/A N/A

Which has preferable valuation and earnings, NAUT or IBAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nautilus Biotechnology N/A N/A -$59M -$0.45 N/A IB Acquisition N/A N/A N/A N/A N/A

Is NAUT or IBAC more profitable?

IB Acquisition's return on equity of 0.00% beat Nautilus Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Nautilus Biotechnology N/A -37.58% -30.83% IB Acquisition N/A N/A N/A

Do analysts rate IBAC or MXCT?

MaxCyte has a consensus target price of $5.00, indicating a potential upside of 320.17%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts plainly believe MaxCyte is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MaxCyte 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, IBAC or MXCT?

IB Acquisition has higher earnings, but lower revenue than MaxCyte. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IB Acquisition N/A N/A N/A N/A N/A MaxCyte $33.03M 3.72 -$44.63M -$0.33 N/A

Does the media prefer IBAC or MXCT?

In the previous week, MaxCyte had 1 more articles in the media than IB Acquisition. MarketBeat recorded 3 mentions for MaxCyte and 2 mentions for IB Acquisition. IB Acquisition's average media sentiment score of 0.83 beat MaxCyte's score of 0.71 indicating that IB Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IB Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MaxCyte 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

IB Acquisition (IBAC) Competitors

$11.32 -0.08 (-0.66%)

As of 09/24/2026 03:59 PM Eastern

Compare

IBAC vs. QSI, QTRX, CDXS, NAUT, and MXCT

Should you buy IB Acquisition stock or one of its competitors? IB Acquisition's main competitors and comparable companies include Quantum-Si (QSI), Quanterix (QTRX), Codexis (CDXS), Nautilus Biotechnology (NAUT), and MaxCyte (MXCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does IB Acquisition compare to Quantum-Si?

IB Acquisition (NASDAQ:IBAC) and Quantum-Si (NASDAQ:QSI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

39.9% of Quantum-Si shares are held by institutional investors. 22.0% of Quantum-Si shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Quantum-Si had 6 more articles in the media than IB Acquisition. MarketBeat recorded 8 mentions for Quantum-Si and 2 mentions for IB Acquisition. IB Acquisition's average media sentiment score of 0.83 beat Quantum-Si's score of 0.16 indicating that IB Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IB Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quantum-Si	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IB Acquisition has a net margin of 0.00% compared to Quantum-Si's net margin of -6,138.26%. IB Acquisition's return on equity of 0.00% beat Quantum-Si's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IB Acquisition	N/A	N/A	N/A
Quantum-Si	-6,138.26%	-47.12%	-43.18%

Quantum-Si has a consensus target price of $1.00, indicating a potential upside of 27.39%. Given Quantum-Si's stronger consensus rating and higher probable upside, analysts plainly believe Quantum-Si is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IB Acquisition has higher earnings, but lower revenue than Quantum-Si.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IB Acquisition	N/A	N/A	N/A	N/A	N/A
Quantum-Si	$2.44M	70.42	-$101.34M	-$0.46	N/A

Summary

Quantum-Si beats IB Acquisition on 7 of the 11 factors compared between the two stocks.

How does IB Acquisition compare to Quanterix?

Quanterix (NASDAQ:QTRX) and IB Acquisition (NASDAQ:IBAC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Quanterix presently has a consensus price target of $3.00, suggesting a potential downside of 5.66%. Given Quanterix's stronger consensus rating and higher probable upside, equities research analysts plainly believe Quanterix is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IB Acquisition has a net margin of 0.00% compared to Quanterix's net margin of -80.25%. IB Acquisition's return on equity of 0.00% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-80.25%	-26.09%	-19.03%
IB Acquisition	N/A	N/A	N/A

In the previous week, Quanterix had 2 more articles in the media than IB Acquisition. MarketBeat recorded 4 mentions for Quanterix and 2 mentions for IB Acquisition. IB Acquisition's average media sentiment score of 0.83 beat Quanterix's score of 0.46 indicating that IB Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quanterix	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IB Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.5% of Quanterix shares are owned by institutional investors. 1.5% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

IB Acquisition has lower revenue, but higher earnings than Quanterix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$138.90M	1.08	-$107.15M	-$2.63	N/A
IB Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Quanterix beats IB Acquisition on 6 of the 10 factors compared between the two stocks.

How does IB Acquisition compare to Codexis?

Codexis (NASDAQ:CDXS) and IB Acquisition (NASDAQ:IBAC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Codexis currently has a consensus target price of $6.50, suggesting a potential upside of 374.45%. Given Codexis' stronger consensus rating and higher probable upside, equities analysts plainly believe Codexis is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IB Acquisition has a net margin of 0.00% compared to Codexis' net margin of -39.55%. IB Acquisition's return on equity of 0.00% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
IB Acquisition	N/A	N/A	N/A

In the previous week, IB Acquisition had 1 more articles in the media than Codexis. MarketBeat recorded 2 mentions for IB Acquisition and 1 mentions for Codexis. Codexis' average media sentiment score of 1.77 beat IB Acquisition's score of 0.83 indicating that Codexis is being referred to more favorably in the media.

Company	Overall Sentiment
Codexis	Very Positive
IB Acquisition	Positive

78.5% of Codexis shares are held by institutional investors. 3.5% of Codexis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

IB Acquisition has lower revenue, but higher earnings than Codexis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.13	-$43.97M	-$0.34	N/A
IB Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Codexis beats IB Acquisition on 7 of the 11 factors compared between the two stocks.

How does IB Acquisition compare to Nautilus Biotechnology?

Nautilus Biotechnology (NASDAQ:NAUT) and IB Acquisition (NASDAQ:IBAC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

50.7% of Nautilus Biotechnology shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

IB Acquisition's return on equity of 0.00% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
IB Acquisition	N/A	N/A	N/A

In the previous week, IB Acquisition had 1 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 2 mentions for IB Acquisition and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 1.82 beat IB Acquisition's score of 0.83 indicating that Nautilus Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Nautilus Biotechnology	Very Positive
IB Acquisition	Positive

Nautilus Biotechnology currently has a consensus target price of $4.00, indicating a potential upside of 303.84%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, equities research analysts plainly believe Nautilus Biotechnology is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A
IB Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Nautilus Biotechnology beats IB Acquisition on 6 of the 9 factors compared between the two stocks.

How does IB Acquisition compare to MaxCyte?

IB Acquisition (NASDAQ:IBAC) and MaxCyte (NASDAQ:MXCT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

MaxCyte has a consensus target price of $5.00, indicating a potential upside of 320.17%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts plainly believe MaxCyte is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, MaxCyte had 1 more articles in the media than IB Acquisition. MarketBeat recorded 3 mentions for MaxCyte and 2 mentions for IB Acquisition. IB Acquisition's average media sentiment score of 0.83 beat MaxCyte's score of 0.71 indicating that IB Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IB Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IB Acquisition has higher earnings, but lower revenue than MaxCyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IB Acquisition	N/A	N/A	N/A	N/A	N/A
MaxCyte	$33.03M	3.72	-$44.63M	-$0.33	N/A

IB Acquisition has a net margin of 0.00% compared to MaxCyte's net margin of -114.77%. IB Acquisition's return on equity of 0.00% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IB Acquisition	N/A	N/A	N/A
MaxCyte	-114.77%	-18.92%	-16.14%

68.8% of MaxCyte shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

MaxCyte beats IB Acquisition on 7 of the 11 factors compared between the two stocks.

Get IB Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBAC vs. The Competition

Export

Metric	IB Acquisition	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$57.60M	$10.51B	$7.31B	$13.29B
Dividend Yield	N/A	1.45%	2.52%	12.57%
P/E Ratio	N/A	75.12	274.39	25.76
Price / Sales	N/A	110.26	685.35	111.79
Price / Cash	N/A	27.90	77.80	52.76
Price / Book	N/A	6.08	10.47	6.34
Net Income	N/A	$56.67B	$3.49B	$360.00M
7 Day Performance	-2.71%	3.11%	-0.91%	-0.18%
1 Month Performance	4.38%	3.18%	-4.21%	-4.09%
1 Year Performance	6.63%	40.73%	16.41%	5.97%

IB Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBAC IB Acquisition	N/A	$11.32 -0.7%	N/A	+6.6%	$57.60M	N/A	N/A	2
QSI Quantum-Si	2.9971 of 5 stars	$0.75 -3.2%	$1.00 +34.2%	-51.2%	$168.54M	$2.44M	N/A	145
QTRX Quanterix	0.6816 of 5 stars	$3.07 -1.6%	$3.00 -2.3%	-40.0%	$147.55M	$138.90M	N/A	450
CDXS Codexis	2.6927 of 5 stars	$1.36 +3.0%	$6.50 +377.9%	-44.8%	$144.55M	$70.39M	N/A	146	News Coverage Positive News High Trading Volume
NAUT Nautilus Biotechnology	2.707 of 5 stars	$0.97 -0.6%	$4.00 +314.1%	+37.6%	$123.65M	N/A	N/A	130	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBAC) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IB Acquisition (IBAC) Competitors

IBAC vs. QSI, QTRX, CDXS, NAUT, and MXCT

How does IB Acquisition compare to Quantum-Si?

Summary

How does IB Acquisition compare to Quanterix?

Summary

How does IB Acquisition compare to Codexis?

Summary

How does IB Acquisition compare to Nautilus Biotechnology?

Summary

How does IB Acquisition compare to MaxCyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBAC vs. The Competition

IB Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IB Acquisition (IBAC) Competitors

IBAC vs. QSI, QTRX, CDXS, NAUT, and MXCT

How does IB Acquisition compare to Quantum-Si?

Do insiders and institutionals believe in IBAC or QSI?

Does the media prefer IBAC or QSI?

Is IBAC or QSI more profitable?

Do analysts prefer IBAC or QSI?

Which has better valuation and earnings, IBAC or QSI?

Summary

How does IB Acquisition compare to Quanterix?

Do analysts prefer QTRX or IBAC?

Is QTRX or IBAC more profitable?

Does the media favor QTRX or IBAC?

Do insiders and institutionals hold more shares of QTRX or IBAC?

Which has preferable earnings and valuation, QTRX or IBAC?

Summary

How does IB Acquisition compare to Codexis?

Do analysts rate CDXS or IBAC?

Is CDXS or IBAC more profitable?

Does the media prefer CDXS or IBAC?

Do institutionals & insiders believe in CDXS or IBAC?

Which has better earnings and valuation, CDXS or IBAC?

Summary

How does IB Acquisition compare to Nautilus Biotechnology?

Do institutionals and insiders have more ownership in NAUT or IBAC?

Is NAUT or IBAC more profitable?

Does the media refer more to NAUT or IBAC?

Do analysts recommend NAUT or IBAC?

Which has preferable valuation and earnings, NAUT or IBAC?

Summary

How does IB Acquisition compare to MaxCyte?

Do analysts rate IBAC or MXCT?

Does the media prefer IBAC or MXCT?

Which has stronger earnings and valuation, IBAC or MXCT?

Is IBAC or MXCT more profitable?

Do institutionals & insiders have more ownership in IBAC or MXCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBAC vs. The Competition

IB Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools